Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22283041 | 1.00 | BACE1 (0.40) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL19239617 | 1.00 | BACE1 (0.40) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL12245284 | 1.00 | BACE1 (0.40) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL29768879 | 0.91 | NPC1 (0.40) | KMT2AMEN1LMNASMN1; SMN2NPC1 | |
| SCHEMBL29895834 | 0.89 | BACE1 (0.37) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL21858972 | 0.89 | HTT (0.41) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL19211624 | 0.89 | HTT (0.41) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL17196627 | 0.89 | MEN1 (0.45) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL17918547 | 0.89 | MEN1 (0.43) | BACE1HTTKMT2AMEN1LMNA | |
| SCHEMBL20149309 | 0.86 | HTT (0.50) | HTTKMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-12 | — | — | US | disclosed |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-3690038-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | BACE1 4189/4885HTT 4778/4885KMT2A 3198/4885 |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | BACE1 4219/4885HTT 4084/4885KMT2A 1977/4885 |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | GABRA1, GABRA4, GABRA2 | BACE1 855/4885HTT 3093/4885KMT2A 777/4885 |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | BACE1 4219/4885HTT 4084/4885KMT2A 1977/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | BACE1 4267/4885HTT 4354/4885KMT2A 2405/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | BACE1 4219/4885HTT 4084/4885KMT2A 1977/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | BACE1 2666/4885HTT 3963/4885KMT2A 3107/4885 |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | BACE1 4219/4885HTT 4084/4885KMT2A 1977/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | BACE1 2696/4885HTT 3962/4885KMT2A 3126/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | BACE1 4362/4885HTT 4507/4885KMT2A 2063/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | BACE1 4219/4885HTT 4084/4885KMT2A 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.